Widespread alternative polyadenylation regulation reprograms the prostate cancer cell transcriptome upon androgen receptor inhibition.

Prostate cancer (PC) onset and progression relies on the androgen receptor (AR) signaling. Anti-androgenic hormonal therapy (HT) is initially efficacious, but most patients evolve to a castration resistant stage (CRPC) for which no cure is currently available. Most proposed mechanisms of acquired resistance to HT focus on the transcriptional activity in CRPC cells. In this study, however, we have uncovered a new role of AR in alternative cleavage and polyadenylation (APA) regulation. We have profiled the global effect of Enzalutamide on alternative polyadenylation by 3’READS-seq analysis using RNA isolated from LNCaP cells following 24 hours treatment with Enzalutamide or vehicle control DMSO (3 biological replicates).